Effectiveness of early intensive therapy onb-cell preservation in type 1 diabetes

Diabetes Care

Volumn 36, Issue 12, 2013, Pages 4030-4035

  Buckingham, Bruce ^a   Beck, Roy W ^b   Ruedy, Katrina J ^b   Cheng, Peiyao ^b   Kollman, Craig ^b   Weinzimer, Stuart A ^c   DiMeglio, Linda A ^d   Bremer, Andrew A ^e   Slover, Robert ^f   Tamborlane, William V ^c  

^a STANFORD UNIVERSITY   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c YALE UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; CONCENTRATION (PARAMETERS); CONTINUOUS GLUCOSE MONITOR; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; GLUCOSE TOLERANCE TEST; HUMAN; HYBRID CLOSED LOOP CONTROL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTENSIVE CARE; LYMPHOCYTE PRESERVATION; MAJOR CLINICAL STUDY; MALE; MIXED MEAL TOLERANCE TEST; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; SENSOR AUGMENTED PUMP; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; FOLLOW UP; INSULIN INFUSION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891859307     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1074     Document Type: Article

References (29)

1. Steffes MW, Sibley S, Jackson M, Thomas W. β-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836
2. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual b-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523
3. Mirouze J, Selam JL, Pham TC, Mendoza E, Orsetti A. Sustained insulin-induced remissions of juvenile diabetes by means of an external artificial pancreas. Diabetologia 1978;14:223-227
4. Like A. Insulin injections prevent diabetes (DB) in biobreeding/worcester (BB/Wor) rats. Diabetes 1986;35:74A
5. Appel MC, O'Neil JJ. Prevention of spontaneous diabetes in the bb/w rat by insulin treatment. Pancreas 1986;1:356-368
6. Gotfredsen CF, Buschard K, Frandsen EK. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985;28:933-935
7. Bowman MA, Campbell L, Darrow BL, Ellis TM, Suresh A, Atkinson MA. Immunological and metabolic effects of prophylactic insulin therapy in the NODscid/scid adoptive transfer model of IDDM. Diabetes 1996;45:205-208
8. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetesmellitus. N Engl JMed 1989;320: 550-554
9. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 1986; 35:530-545
10. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31: 934-939
11. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344-3350
12. Steil GM, Panteleon AE, Rebrin K. Closedloop insulin delivery-the path to physiological glucose control. Adv Drug Deliv Rev 2004;56:125-144
13. Ruiz JL, Sherr JL, Cengiz E, et al. Effect of insulin feedback on closed-loop glucose control: a crossover study. J Diabetes Sci Tech 2012;6:1123-1130
14. Steil GM, Palerm CC, Kurtz N, et al. The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011;96:1402-1408
15. Loutseiko M, Voskanyan G, Keenan DB, Steil GM. Closed-loop insulin delivery utilizing pole placement to compensate for delays in subcutaneous insulin delivery. J Diabetes Sci Tech 2011;5:1342-1351
16. Buckingham BA, Beck RW, Ruedy KJ, et al.; Diabetes Research in Children Network (Direc Net) Study Group; Type 1 Diabetes Trial Net Study Group. The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther 2013;15:401-408
17. Buckingham B, Xing D, Weinzimer S, et al.; Diabetes Research In Children Network (Direc Net) Study Group. Use of the Direc Net Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the Free Style Navigator). Pediatr Diabetes 2008;9:142-147
18. Palmer J, Fleming G, Greenbaum C, et al. C-peptide Is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function [published correction appears in Diabetes 2004;53: 1934]. Diabetes 2004;53:250-264
19. Lachin JM, McGee PL, Greenbaum CJ, et al.; Type 1 Diabetes Trial Network. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes. PLoS ONE 2011;6:e26471
20. Buckingham B, Beck RW, Tamborlane WV, et al.; Diabetes Research in Children Network (Direc Net) Study Group. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr 2007;151: 388-393, e1-e2
21. Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes Trial Net Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes Trial Net data. Diabetes 2012; 61:2066-2073
22. Kordonouri O, Pankowska E, Rami B, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 2010;53:2487-2495
23. Schnell O, Eisfelder B, Standl E, Ziegler AG. High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM. Diabetes 1997;46:1607-1611
24. de Beaufort CE, Houtzagers CM, Bruining GJ, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med 1989;6:766-771
25. Edelmann E, Walter H, Biermann E, Schleicher E, Bachmann W, Mehnert H. Sustained normoglycemia and remission phase in newly diagnosed type I diabetic subjects. Comparison between continuous subcutaneous insulin infusion and conventional therapy during a one year followup. Horm Metab Res 1987;19:419-421
26. Krarup T, Madsbad S. Effect of two periods with intensified insulin treatment on B-cell function during the first 18 months of type 1 (insulin-dependent) diabetes mellitus. Diabete Metab 1986;12:256-260
27. Perlman K, Ehrlich RM, Filler RM, Albisser AM. Sustained normoglycemia in newly diagnosed type I diabetic subjects. Short-term effects and one-year followup. Diabetes 1984;33:995-1001
28. Flores d'Arcais A, Morandi F, Beccaria L, Meschi F, Chiumello G. Metabolic control in newly diagnosed type 1 diabetic children. Effect of continuous subcutaneous infusion. Horm Res 1984;19:65-69
29. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 2002;109:45-60